The global uropathy treatment market size was estimated to be USD 4.52 billion in 2023 and is expected to reach USD 7.04 billion by 2034 with a CAGR of 4.11% during the forecast period 2024-2034. The rising prevalence of urological disorders, rising technological advancements, growing geriatric population, increasing awareness and early detection, focus on personalized medicine, and strategic partnerships and collaborations will drive the market growth.
Aging-related urological problems are more common as the population ages. Education and public health campaigns bring urological diseases and the value of early diagnosis to the public's attention they are modifying treatment programs following the unique traits and genetic profiles of each patient to get better results. For instance, Pfizer Inc. announced in October 2023 that the FDA had approved Xtandi® (enzalutamide) for the treatment of prostate cancer that is not metastatic and is resistant to castration (nmCRPC). This greatly increases the drug's business potential and reach.
By treatment, the drugs segment accounted for the highest revenue-grossing segment in the global uropathy treatment market in 2023 owing to the absence of conclusive scientific evidence supporting the efficacy and safety of uropathy, leading to a prevailing reliance on traditional pharmaceutical interventions for urological conditions and contributing to the dominance of the drugs segment in the market. For instance, in December 2023, Johnson & Johnson paid $16.6 billion to acquire Abiomed, Inc., a market leader in heart and vascular support technology. Through Abiomed's cutting-edge Impella heart pumps, which are employed in the treatment of urosepsis, J&J's urology portfolio is strengthened. Additionally, the devices segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing technological advancements and innovations in urological devices, rising demand for minimally invasive procedures, and a growing emphasis on enhancing patient outcomes and comfort.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global uropathy treatment market in 2023 owing to the increased prevalence of urological disorders requiring comprehensive medical care, a growing patient preference for professional medical supervision, and the availability of advanced diagnostic and treatment facilities within hospitals and clinics. For instance, in November 2023, Zenpep® (pancrelipase) favorable Phase 3 data was presented by GlaxoSmithKline plc for the treatment of pancreatic exocrine insufficiency (PEI) linked to cystic fibrosis. In addition to this, Zenpep's market may grow beyond the individuals with chronic pancreatitis for whom it is now prescribed. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for outpatient procedures, advancements in surgical technologies promoting shorter recovery times, and a shift towards cost-effective and convenient healthcare options.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increasing prevalence of urological disorders, a high level of awareness and adoption of advanced medical treatments, and continuous research and development activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising healthcare investments, expanding patient population, growing awareness about urological conditions, and improving healthcare infrastructure. For example, Novartis AG and Genmab A/S collaborated to develop and commercialize nipocalimab in January 2024. Nipocalimab is a potential first-in-class treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but serious autoimmune disease that can affect the kidneys.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Aging-related urological problems are more common as the population ages. Education and public health campaigns bring urological diseases and the value of early diagnosis to the public's attention they are modifying treatment programs following the unique traits and genetic profiles of each patient to get better results. For instance, Pfizer Inc. announced in October 2023 that the FDA had approved Xtandi® (enzalutamide) for the treatment of prostate cancer that is not metastatic and is resistant to castration (nmCRPC). This greatly increases the drug's business potential and reach.
By treatment, the drugs segment accounted for the highest revenue-grossing segment in the global uropathy treatment market in 2023 owing to the absence of conclusive scientific evidence supporting the efficacy and safety of uropathy, leading to a prevailing reliance on traditional pharmaceutical interventions for urological conditions and contributing to the dominance of the drugs segment in the market. For instance, in December 2023, Johnson & Johnson paid $16.6 billion to acquire Abiomed, Inc., a market leader in heart and vascular support technology. Through Abiomed's cutting-edge Impella heart pumps, which are employed in the treatment of urosepsis, J&J's urology portfolio is strengthened. Additionally, the devices segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing technological advancements and innovations in urological devices, rising demand for minimally invasive procedures, and a growing emphasis on enhancing patient outcomes and comfort.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global uropathy treatment market in 2023 owing to the increased prevalence of urological disorders requiring comprehensive medical care, a growing patient preference for professional medical supervision, and the availability of advanced diagnostic and treatment facilities within hospitals and clinics. For instance, in November 2023, Zenpep® (pancrelipase) favorable Phase 3 data was presented by GlaxoSmithKline plc for the treatment of pancreatic exocrine insufficiency (PEI) linked to cystic fibrosis. In addition to this, Zenpep's market may grow beyond the individuals with chronic pancreatitis for whom it is now prescribed. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for outpatient procedures, advancements in surgical technologies promoting shorter recovery times, and a shift towards cost-effective and convenient healthcare options.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increasing prevalence of urological disorders, a high level of awareness and adoption of advanced medical treatments, and continuous research and development activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising healthcare investments, expanding patient population, growing awareness about urological conditions, and improving healthcare infrastructure. For example, Novartis AG and Genmab A/S collaborated to develop and commercialize nipocalimab in January 2024. Nipocalimab is a potential first-in-class treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but serious autoimmune disease that can affect the kidneys.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Treatment, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Uropathy Treatment Market Report 2023 - 2034
Uropathy Treatment Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Devices
- Stents
- Catheters
- Implants
- Robotic Platforms
- Drugs
- Anti-Infectives
- Pain Medications
- Alpha-Blockers
- Hormonal Therapies
Uropathy Treatment Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals and Clinics
- Ambulatory Surgical Centers
- others
Uropathy Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Uropathy Treatment Market: Treatment Estimates & Trend Analysis
8. Uropathy Treatment Market: End-User Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Uropathy Treatment Market
11. Europe Global Uropathy Treatment Market
12. Asia Pacific Global Uropathy Treatment Market
13. Latin America Global Uropathy Treatment Market
14. MEA Global Uropathy Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline plc
- Novartis AG
- AstraZeneca
- Boston Scientific Corporation
- Siemens Healthineers
- Medtronic plc
- Roche Holdings AG
- Abbott Laboratories
- Olympus Corporation
- Sanofi
- Eli Lilly and Company
- Astellas Pharma Inc.
- Merck & Co. Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.52 Billion |
| Forecasted Market Value ( USD | $ 7.04 Billion |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
